FDA Set to Halt Covid Drugs Seen Ineffective Against Omicron.

(Bloomberg) -- The Food and Drug Administration is poised to halt use of two monoclonal antibody therapies that are believed to be ineffective against the omicron variant, according to people familiar with the matter, a move that will lead the federal government to pause shipments of the treatments to states. On Jan. 5, DeSantis told reporters that "with omicron, there's not enough evidence" that the Regeneron and Lilly therapies aren't effective. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)